Expanding Partnerships with Major Industry Players
ITASCA,
Ill., Jan. 21, 2025 /PRNewswire/ -- Lakeside
Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a
U.S.-based cross-border supply chain solution provider with a
unique focus on the Asia-Pacific
market is pleased to announce that its wholly owned subsidiary,
Hupan Pharmaceutical (Hubei) Co.,
Ltd. ("Hupan Pharmaceutical"), has entered into two distribution
agreements with Hubei Kelun Pharmaceutical Trading Co., Ltd., a
subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd., a publicly
traded company on the Shenzhen Stock Exchange (002422.SZ),
principally engaged in the research and development, manufacture
and distribution of pharmaceutical products.
Under the agreements, Hupan Pharmaceutical will
distribute basic large-volume parenteral solutions, along with
related medical products and equipment, to healthcare institutions
across China. The agreements,
effective from January 1, 2025, to
December 31, 2025, further expand
Hupan Pharmaceutical's portfolio of medical distribution
clients.
These contracts with Kelun Pharmaceutical represent another
milestone for Lakeside, following its recent agreement with Sichuan
Huiyu Pharmaceutical Co., Ltd. ("Huiyu Pharmaceutical"), a leader
in oncology and immune-related therapies. This continued momentum
highlights Hupan Pharmaceutical's ability to forge relationships
with major pharmaceutical players, further strengthening its
position in the pharmaceutical distribution sector.
Lan Su, Chief Operating Officer
of Lakeside commented, "These agreements with Kelun Pharmaceutical
build on the success of our other recent agreements. We appreciate
earning the trust of leading pharmaceutical companies to deliver
critical medical products efficiently, ensuring they reach the
patients who need them most."
About Lakeside Holding Limited
Lakeside Holding Limited is a U.S.-based cross-border supply
chain solution provider with a unique focus on the Asia-Pacific market. Through two specialized
subsidiaries—American Bear Logistics and Hupan Pharmaceutical
(Hubei) Co., Ltd.—Lakeside
delivers tailored logistics solutions spanning general and
specialized sectors.
American Bear Logistics, with strategic hubs in Chicago, Dallas, Los
Angeles, and New York,
offers customized cross-border ocean and airfreight solutions,
connecting Asia-based logistics
service companies and e-commerce platforms with the U.S.
market.
Lakeside recently acquired Hupan Pharmaceutical (Hubei) Co., Ltd., expanding its service scope
and enhancing its pharmaceutical logistics and distribution
capabilities within China. This
strategic move underscores Lakeside's commitment to advancing
integrated cross-border logistics solutions.
For more information, please
visit https://lakeside-holding.com.
Safe Harbor Statement
This press release contains forward-looking statements that
reflect our current expectations and views of future events. Known
and unknown risks, uncertainties and other factors, including those
listed under "Risk Factors," may cause our actual results,
performance or achievements to be materially different from those
expressed or implied by the forward-looking statements. You can
identify some of these forward-looking statements by words or
phrases such as "may," "will," "expect," "anticipate," "aim,"
"estimate," "intend," "plan," "believe," "is/are likely to,"
"potential," "continue" or other similar expressions. We have based
these forward-looking statements largely on our current
expectations and projections about future events that we believe
may affect our financial condition, results of operations, business
strategy and financial needs. These forward-looking statements
involve various risks and uncertainties. Except as required by law,
we undertake no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise, after the date on which the statements
are made or to reflect the occurrence of unanticipated events. We
qualify all of our forward-looking statements by these cautionary
statements.
Investor Relations Contact:
Matthew Abenante, IRC
President
Strategic Investor Relations, LLC
Tel: 347-947-2093
Email: matthew@strategic-ir.com
View original
content:https://www.prnewswire.com/news-releases/lakeside-secures-new-distribution-agreements-with-kelun-pharmaceutical-302355442.html
SOURCE Lakeside Holding Limited